Resectable Pancreatic Cancer
Conditions
Keywords
circulating tumor DNA, kinetic, pancreatic cancer, pancreatoduodenectomy, Next Generation Sequencing
Brief summary
Pancreatic cancer represents the fourth cause of death by cancer in western countries. The only curative treatment is surgery but this one is possible only in 10 to 15 % of cases. To date, there are few biomarkers in circulating blood as prognostic or diagnostic markers in pancreatic cancer. The purpose of this study is to determine if the pancreatic tumor mobilization during its resection impacts the quantity of circulating tumor DNA in peripheral and portal blood.
Detailed description
The investigators will analyze if the tumor mobilization increases circulating DNA rate in peripheral and portal blood. Moreover, circulating tumor DNA will be measured during 12 months after surgery in peripheral blood. They will use a gene mutation detection technique called Next Generation Sequencing (NGS) which is more specific than a simple Polymerase Chain Reaction (PCR).
Interventions
OTHERBlood samples
Blood samples will be taken to analyze the circulating tumor DNA rate by NGS
Sponsors
University Hospital, Toulouse
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Every patient taken care by Toulouse University Hospital for the resection of a non-metastatic pancreatic adenocarcinoma by whipple resection. * Patient aged over 18 years old * Patient having given his written consent * Patient with social insurance coverage
Exclusion criteria
* Patients who had surgery, but their pathological examination of the resected specimen does not contain adenocarcinoma. * Patient for whom the surgery was not realized (exploratory laparotomy)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Kinetic of circulating tumor DNA evaluation in resected pancreatic cancer. | Kinetic up to one year | To analyse circulating tumor DNA rate in the portal vein and in peripheral blood at various times of pancreatic cancer resection. Kinetic to 1 day before surgery, during surgery and after surgery (1 day, 10days , one month, 3 months, 6 months and one year after surgery) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | Kinetic up to one year | to analyse correlation between circulating tumor DNA rate and overall survival and survival without recurrence. Kinetic to 1 day before surgery, during surgery and after surgery (1 day, one month, 3 months, 6 months and one year after surgery) |
| Correlation between circulating tumor DNA rate and Ca19.9 dosage | Kinetic up to one year | to analyse correlation between circulating tumor DNA and Ca19.9 rate after dosage of C19.9. Kinetic to 1 day before surgery, and after surgery (on day, one month, 3 months, 6 months and one year after surgery) |
Countries
France
Outcome results
None listed